INBX in the 13F filings
Inhibrx Biosciences Inc · CUSIP 45720N103
- Quarter end
- 30 Jun 2026
- the date the book describes
- Filed
- 2 Sep 2026
- latest of these filings; the earliest 12 Aug 2026
- Managers listing it
- 24
- at least, of 95 tracked, among listed positions
- Comparable managers
- 91
- filed both Q1 2026 and Q2 2026; 4 listed it in both
- Shares listed
- 3,032,796
- combined, among listed positions
- Reported value
- $287m
- combined, at the quarter end
AllianceBernstein LP. Values in this filing are at the previous quarter end's prices; its share count is the quarter end's.
Among the 91 comparable managers: 12 buyers (opened or added shares) and 14 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was -250,794.
Managers listing INBX in Q2 2026
24 of 24 holders
Largest increases and reductions, by shares
Increases
- Schonfeld Strategic Advisors LLCexisting position · 697,586 shares now+442,759
- Voloridge Investment Management LLCexisting position · 48,765 shares now+35,264
- Point72 Asset Management LPnew position · 26,011 shares now+26,011
- Verition Fund Management LLCnew position · 17,993 shares now+17,993
- Woodline Partners LPexisting position · 400,892 shares now+16,459
Reductions
- Viking Global Investors LPexisting position · 1,123,929 shares now-313,776
- Millennium Management LLCexisting position · 147,200 shares now-180,660
- Susquehanna International Group LLPexisting position · 17,272 shares now-80,601
- D. E. Shaw & Co.existing position · 22,322 shares now-55,115
- Fidelity (FMR LLC)existing position · 1,134 shares now-51,674
New positions and exits
New (5)
Exited (3)
- Citadel Advisors LLCwas $2.2m
- Jane Street Group LLCwas $618k
- Tudor Investment Corpwas $496k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2024 | 1 | $25m | 1 | 0 |
| Q3 2024 | 1 | $28m | 0 | 0 |
| Q4 2024 | 1 | $28m | 0 | 0 |
| Q1 2025 | 1 | $25m | 0 | 0 |
| Q2 2025 | 2 | $35m | 1 | 0 |
| Q3 2025 | 2 | $72m | 0 | 1 |
| Q4 2025 | 4 | $175m | 12 | 9 |
| Q1 2026 | 4 | $166m | 12 | 9 |
| Q2 2026 | 4 | $245m | 12 | 14 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
INBX and GILD →INBX and AMGN →INBX and ARGX →Choose a stock to compare with INBX →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own INBX, latest filings →Back to the 13F Explorer →